Effects of Pirarubicin in the Consolidation Chemotherapy of Acute Promyelocytic Leukemia
-
摘要:
目的 探讨吡柔比星巩固治疗急性早幼粒细胞白血病（APL）疗效及不良反应。 方法 回顾性分析2006年1月至2011年8月北京大学深圳医院血液科收治的初治APL患者72例，完全缓解58例，分为TA组（吡柔比星+阿糖胞苷）26例和DA组（柔红霉素+阿糖胞苷）32例，比较两组疗效及不良反应。 结果 58例患者中复发5例，其中TA组1例，DA组4例，虽然无统计学差异，但TA组比DA组2年复发率更低（5.0% vs. 13.0%），3年无病生存率更高（93.3% vs. 76.5%）。两组血液学毒性的发生率及严重程度相似。但心脏毒性方面，TA组仅9.2%（11例）出现轻微短暂心电图T波改变，无1例出现ST-T改变、心律失常或心肌酶升高。心脏不良事件发生率低于DA组。 结论 TA与DA方案巩固治疗APL疗效相似，不良反应两组间无显著差异，吡柔比星心脏毒性更低。TA方案可作为急性早幼粒细胞白血病巩固治疗化疗方案之一。 -
关键词:
- 吡柔比星 /
- 急性早幼粒细胞白血病 /
- 疗效
Abstract:Objective To explore the effectiveness and side effects of pirarubicin in the consolidation chemotherapy of acute promyelocytic leukemia (APL). Methods We retrospectively studied 58 cases of newly diagnosed APL that achieved complete remission (CR). The patients were divided into two groups, with 26 cases in the TA group (pirarubicin + cytarabin), and 32 cases in the DA group (daunorubicin + cytarabin). Results Of the 58 patients, 5 relapsed: 1 case in the TA group and 4 cases in DA group. Although no significant difference was observed between the Objective: two groups, the 2-year cumulative incidence of relapse was lower in the TA group than the DA group (5.0 % vs. 13.0 %). The 3-year event free survival (EFS) was higher in the TA group (93.3 % vs. 76.5 %). The incidence and the degree of hematologic toxicity were similar. A mild transient T-wave abnormality was observed in 9.2% of the chemotherapy cycles in the TA group. The TA group had a lower incidence of cardiac toxicity than the DA group. Conclusion The TA and DA regimens have similar effects on the consolidation chemotherapy of APL. The difference in side effects between the two groups was not significant. Pirarubicin has a lower incidence of cardiac toxicity. The TA regimen (pirarubicin + cytarabin) may be an alternative to APL consolidation therapy. -
Key words:
- Pirarubicin /
- Acute promyelocytic leukemia /
- Efficacy
-
表 1 APL患者临床特征
Table 1. Clinical characteristics of APL patients
表 2 复发APL患者随访结果
Table 2. Results of follow-up study of relapsed APL
表 3 TA组和DA组血液学毒性发生情况比较
Table 3. Comparison of hematological toxicity between the TA and DA groups
-
[1] 张之南, 沈悌, 主编. 血液病诊断及疗效标准[M]. 3版. 北京: 科学出版社, 2008: 106-133. [2] Sanz MA, Lo Coco F, Martin G, et al. Definition of relapse risk and role of non-anthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups[J]. Blood, 2000, 96(4): 1247-1253. http://www.ncbi.nlm.nih.gov/pubmed/10942364 [3] 伍艳萍, 刘锐棠, 余莉. 三氧化二砷治疗急性早幼粒细胞白血病心脏毒性的临床分析[J]. 海南医学, 2010, 21(10): 13-16. doi: 10.3969/j.issn.1003-6350.2010.10.005 [4] 王彦艳, 沈晓梅, 张荣艳, 等. 吡柔比星为主联合化疗方案治疗初治急性髓系白血病疗效观察——一项前瞻、开放、随机、多中心临床研究[J]. 中华血液学杂志, 2010, 31(11): 748-751. doi: 10.3760/cma.j.issn.0253-2727.2010.11.008 [5] 陈黎, 孙慧, 甘思林, 等. 吡柔比星联合阿糖胞苷治疗初治成人急性髓细胞白血病的临床观察[J]. 中国实用医刊, 2010, 37(20): 81-82. [6] 姜尔烈, 黄勇, 庞爱明, 等. 以吡喃阿霉素为基础的联合化疗方案治疗急性髓系白血病的疗效及其预后因素分析[J]. 肿瘤, 2008, 28(6): 532-534. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZLL200806021.htm [7] Kudo K, Kojima S, Tabuehi K, et al. Prospective study of a pirarubicin, intermediate-dose cytarabine, and etopeside regmen in children with Down syndrome and acute myeloid leukemia: the Japanese Childhood AML Cooperative Study Group[J]. J Clin Oncol, 2007, 25(34): 5442-5447. http://onlinelibrary.wiley.com/resolve/reference/PMED?id=18048827 [8] 王艳丽, 秦平, 陈峰, 等. TAE和MAE方案治疗复发难治性急性白血病的前瞻性随机对照研究[J]. 中华血液学杂志, 2010, 31(9): 624-626. doi: 10.3760/cma.j.issn.0253-2727.2010.09.013 [9] 江晓工, 王伯余, 黄志红. 全反式维A酸并用吡柔比星+阿糖胞苷方案诱导缓解急性早幼粒细胞白血病的临床观察[J]. 肿瘤研究与临床, 2005, 17(6): 403-404. doi: 10.3760/cma.j.issn.1006-9801.2005.06.018 [10] 中华医学会血液学分会. 急性早幼粒细胞白血病中国诊疗指南(2011版)[J]. 中华血液学杂志, 2011, 32(12): 885-886. doi: 10.3760/cma.j.issn.0253-2727.2011.12.022 [11] 中华医学会血液学分会. 成人急性髓系白血病(非急性早幼粒细胞白血病)中国诊疗指南(2011版)[J]. 中华血液学杂志, 2011, 32(11): 804-807. doi: 10.3760/cma.j.issn.0253-2727.2011.11.021 -
点击查看大图
表(3)
计量
- 文章访问数: 8
- HTML全文浏览量: 2
- PDF下载量: 0
- 被引次数: 0
下载:
